TRIANA Biomedicines
Benjamin Vincent is a highly experienced Principal Scientist in Oncology at TRIANA Biomedicines since July 2022, previously serving as Senior Scientist II in the same field. Prior experience includes a role as Senior Scientist I in Drug Discovery at Rheos Medicines from November 2020 to July 2022, where Benjamin led the program for RHX-552 targeting autoimmune and inflammatory diseases. This role involved developing high-throughput screening assays and managing extensive compound testing. At Yumanity Therapeutics, Benjamin contributed significantly as Staff Scientist I-II from March 2015 to October 2020, co-discovering YTX-7739 for Parkinson’s disease and establishing the discovery platform for the company. Educational qualifications include a Ph.D. in Microbiology from the Massachusetts Institute of Technology and a Bachelor’s Degree in Biology from Stanford University.
This person is not in any offices
TRIANA Biomedicines
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.